We are live on ! Find out more
ABEO icon

Abeona Therapeutics

104 hedge funds and large institutions have $205M invested in Abeona Therapeutics in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 31 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

143% more call options, than puts

Call options by funds: $8.88M | Put options by funds: $3.65M

22% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 18

19% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 31

9% more capital invested

Capital invested by funds: $188M → $205M (+$17.3M)

4% more funds holding

Funds holding: 100104 (+4)

2.45% more ownership

Funds ownership: 69.4%71.85% (+2.4%)

Holders
104
Holders Change
+4
Holders Change %
+4%
% of All Funds
1.26%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
22
Increased
37
Reduced
31
Closed
18
Calls
$8.88M
Puts
$3.65M
Net Calls
+$5.23M
Net Calls Change
-$1.39M
Name Holding Trade Value Shares
Change
Change in
Stake
RC
51
Rangeley Capital
Connecticut
$304K +$290K +57,600 New
CM
52
Caption Management
Oklahoma
$301K +$287K +57,031 New
N
53
Nuveen
North Carolina
$299K
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$295K -$39K -7,742 -12%
XT
55
XTX Topco
Cayman Islands
$260K +$50.2K +9,979 +25%
Wells Fargo
56
Wells Fargo
California
$252K +$104K +20,673 +76%
DM
57
Deerfield Management
New York
$211K +$201K +40,000 New
Deutsche Bank
58
Deutsche Bank
Germany
$207K +$11.6K +2,303 +6%
AC
59
AXQ Capital
New Jersey
$177K +$169K +33,581 New
BIG
60
Brooklyn Investment Group
New York
$138K +$130K +25,779 New
T. Rowe Price Associates
61
T. Rowe Price Associates
Maryland
$128K +$4.88K +969 +4%
MIM
62
MetLife Investment Management
New Jersey
$126K -$13.5K -2,688 -10%
Invesco
63
Invesco
Georgia
$122K +$247 +49 +0.2%
BHCM
64
Brevan Howard Capital Management
Jersey
$114K +$109K +21,707 New
JP Morgan Chase
65
JP Morgan Chase
New York
$112K -$1.31M -260,912 -92%
IIM
66
INTECH Investment Management
Florida
$112K -$19.8K -3,927 -16%
Mirae Asset Global ETFs Holdings
67
Mirae Asset Global ETFs Holdings
Hong Kong
$107K -$1.21K -241 -1%
RP
68
Riverwater Partners
Wisconsin
$102K +$17.7K +3,518 +22%
Cetera Investment Advisers
69
Cetera Investment Advisers
Illinois
$96.2K +$91.9K +18,258 New
AllianceBernstein
70
AllianceBernstein
Tennessee
$94.4K
SPA
71
Sherbrooke Park Advisers
New York
$82K +$17K +3,377 +28%
Manulife (Manufacturers Life Insurance)
72
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$71.9K -$8.87K -1,761 -11%
Envestnet Asset Management
73
Envestnet Asset Management
Illinois
$70.1K +$67K +13,308 New
LCM
74
Legato Capital Management
California
$69.5K +$11.5K +2,290 +21%
Russell Investments Group
75
Russell Investments Group
United Kingdom
$69K +$30.3K +6,013 +85%

ABEO Hedge Fund Activity: Q4 2025 in Review

104 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q4 2025, worth a combined $205M — up 9.2% from $188M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ABEO positions and 18 closed out — a net gain of 4 holders — while 37 added to existing stakes and 31 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $10.1M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $16.1M sold.

  • 104 institutional investors held Abeona Therapeutics (ABEO) as of Q4 2025, up from 100 in Q3 2025.
  • Funds reported $205M of Abeona Therapeutics stock for Q4 2025, up 9.2% quarter-over-quarter.
  • 22 funds opened new Abeona Therapeutics positions in Q4 2025 and 18 closed out, a net change of +4 holders.
  • The largest Abeona Therapeutics buyer in Q4 2025 was AIGH Capital Management, an estimated $10.1M added.
  • The largest Abeona Therapeutics seller in Q4 2025 was Adage Capital Partners, an estimated $16.1M sold.

Based on aggregated 13F filings for Q4 2025.